APA

Alsina M., Trudel S., Furman R. R., Rosen P. J., O'Connor O. A., Comenzo R. L., Wong A., Kunkel L. A., Molineaux C. J. & Goy A. (20130409). A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Alsina Melissa, Trudel Suzanne, Furman Richard R, Rosen Peter J, O'Connor Owen A, Comenzo Raymond L, Wong Alvin, Kunkel Lori A, Molineaux Christopher J and Goy Andre. 20130409. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Alsina M., Trudel S., Furman R. R., Rosen P. J., O'Connor O. A., Comenzo R. L., Wong A., Kunkel L. A., Molineaux C. J. and Goy A. (20130409). A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Alsina Melissa, Trudel Suzanne, Furman Richard R, Rosen Peter J, O'Connor Owen A, Comenzo Raymond L, Wong Alvin, Kunkel Lori A, Molineaux Christopher J and Goy Andre. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20130409.